Oncothyreon reports second quarter 2009 financial results



    SEATTLE, Aug. 12 /CNW/ - Oncothyreon Inc. (NASDAQ:   ONTY) (TSX: ONY) today
reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for
the three months ended June 30, 2009, compared with a net loss of $4.9
million, or $0.25 per basic and diluted share, for the comparable period in
2008. Oncothyreon recorded a non-cash charge of $2.5 million in the three
months ended June 30, 2009 for the change in the fair value of warrants issued
in connection with its May 2009 securities offering. The increase in net loss
for the three-month period was primarily the result of this non-cash charge
and a decrease in revenue described below, partially offset by decreased
operating expenses.
    Oncothyreon reported a net loss of $8.8 million, or $0.43 per basic and
diluted share, for the six months ended June 30, 2009, compared with a net
loss of $10.1 million, or $0.51 per basic and diluted share, for the
comparable period in 2008. The decrease in net loss for the six-month period
was primarily the result of the transfer of manufacturing activities for
Stimuvax(R) to Merck KGaA in December 2008, which resulted in a decrease of
combined research and development and manufacturing expenses partially offset
by a decrease in both contract manufacturing and licensing revenue from
collaborative agreements and the non-cash charge discussed above.
    Total revenue was $31,000 and $35,000, respectively, for the three and
six months ended June 30, 2009, compared to $1.2 million and $3.2 million for
the same periods in 2008. The decrease in revenue was primarily the result of
the transfer of manufacturing of Stimuvax to Merck KGaA in December 2008.
    Total expenses for the three and six months ended June 30, 2009 were $6.4
million and $8.8 million respectively, compared with $6.1 million and $13.2
million for the comparable periods in 2008. Combined research and development
and manufacturing expenses decreased to $2.0 million for the three months
ended June 30, 2009 from $3.4 million for the three months ended June 30,
2008, and to $2.7 million from $7.8 million for the six month periods,
primarily as the result of the cessation of manufacturing activities for
Stimuvax and the transfer of our Edmonton, Alberta facility to Merck KGaA.
General and administrative expenses decreased to $1.7 million in the three
months ended June 30, 2009 from $2.7 million in the three months ended June
30, 2008. General and administrative expenses decreased to $3.5 million in the
first six months of 2009 from $5.4 million in the first six months of 2008,
primarily as a result of expenses in 2008 related to Oncothyreon's
reincorporation in the United States and of fewer personnel in 2009. Decreases
in operating expenses were offset by the $2.5 million non-cash charge
discussed earlier.
    As of June 30, 2009, Oncothyreon's cash and cash equivalents were $22.7
million, compared to $19.2 million at the end of 2008, an increase of $3.5
million, or 18.2 percent. Major contributors to the net change included net
proceeds of $10.1 million from the sale of 3,878,993 shares of Oncothyreon's
common stock and warrants to purchase 2,909,244 shares of Oncothyreon's common
stock, offset by $6.5 million used in operations in the first six months of
2009.
    On August 7, 2009, subsequent to the period covered by this release,
Oncothyreon closed the sale of approximately 2.28 million shares of its common
stock and warrants to purchase approximately 684,000 shares of its common
stock for net proceeds of approximately $14 million.

    Financial Guidance

    Oncothyreon believes the following financial guidance to be correct as of
the date provided. Oncothyreon is providing this guidance as a convenience to
investors and assumes no obligation to update it.
    Expenses in 2009 are expected to be substantially less than in 2008,
primarily as a result of transferring manufacturing and process development
activities for Stimuvax to Merck KGaA and of the previously announced plan to
restrict development activities to PX-478 and PX-866. Oncothyreon currently
expects cash used in operations in 2009 to be approximately $12 million.

    
    Oncothyreon Highlights for 2009

    Oncothyreon's corporate highlights for the year 2009 to date include the
    following:

    -   Expansion of the Phase 3 development program for Stimuvax with the
        initiation of the STRIDE trial in hormone receptor-positive, locally
        advanced, recurrent or metastatic breast cancer by Oncothyreon's
        partner Merck KGaA. Stimuvax is also being studied in the Phase 3
        START trial in non-small cell lung cancer (NSCLC).
    -   Presentation of long-term data for Stimuvax in NSCLC at the
        International Association for the Study of Lung Cancer's 13th World
        Conference on Lung Cancer. The data involved 16 patients who received
        treatment with Stimuvax for between 2 and 8.2 years as part of the
        Phase 2b trial in patients with stage IIIb/IV NSCLC. As of the time
        of data analysis in April 2009, 10 of the 16 studied patients were
        alive without evidence of disease progression, of whom eight
        continued to receive therapy with Stimuvax after 6.3 to 8.2 years.
        The remaining two living patients discontinued Stimuvax therapy after
        2.4 and 5.8 years, respectively, and were without evidence of disease
        progression.
    -   Presentation of preliminary results from the Phase 1 trial of PX-866,
        an inhibitor of PI-3 kinase, at the American Society of Clinical
        Oncology. The data demonstrated inhibition of PI-3 kinase activity at
        low doses, as well as stabilization of disease in six of 24 patients
        with previously progressive disease in the early dose cohorts in this
        ongoing dose escalation trial.
    -   Improvement of Oncothyreon's financial position with the completion
        of two offerings of units consisting of shares of common stock and
        warrants, which generated combined net proceeds to Oncothyreon of
        approximately $24 million.
    -   Strengthening of Oncothyreon's senior management team with the
        addition of Scott Peterson, Ph.D, as Vice President, Research and
        Development, and Diana Hausman, M.D., as Vice President, Clinical
        Development.
    

    Conference Call and Webcast

    Oncothyreon's management will discuss the Company's second quarter 2009
financial results and provide a business update during a conference call
beginning at 1:30 p.m. PT/4:30 p.m. ET today, Wednesday, August 12, 2009. To
listen to a webcast of the discussion, visit www.oncothyreon.com.

    About Oncothyreon

    Oncothyreon is a biotechnology company specializing in the development of
innovative therapeutic products for the treatment of cancer. Oncothyreon's
goal is to develop and commercialize novel synthetic vaccines and targeted
small molecules that have the potential to improve the lives and outcomes of
cancer patients. For more information, visit www.oncothyreon.com.

    Forward-Looking Statements

    In order to provide Oncothyreon's investors with an understanding of our
current results and future prospects, this release may contain statements that
are forward-looking. Any statements contained in this press release that are
not statements of historical fact may be deemed to be forward-looking
statements. Words such as "believes," "anticipates," "plans," "expects,"
"will," "intends," "potential," "possible" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements include our expectations regarding future expenses, clinical
development activities and the use and adequacy of cash resources.
    Forward-looking statements involve risks and uncertainties related to our
business and the general economic environment, many beyond our control. These
risks, uncertainties and other factors could cause our actual results to
differ materially from those projected in forward-looking statements,
including the risks associated with the costs and expenses of developing our
product candidates, the adequacy of financing and cash reserves on hand,
changes in general accounting policies, general economic factors, achievement
of the results we anticipate from our clinical trials with our products and
our ability to adequately obtain and protect our intellectual property rights.
Although we believe that the forward-looking statements contained herein are
reasonable, we can give no assurance that our expectations are correct. All
forward-looking statements are expressly qualified in their entirety by this
cautionary statement. For a detailed description of our risks and
uncertainties, you are encouraged to review the official corporate documents
filed with the securities regulators in the United States on U.S. EDGAR and in
Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly
update its forward-looking statements based on events or circumstances after
the date hereof.

    Additional Information

    Additional information relating to Oncothyreon can be found on U.S. EDGAR
at www.sec.gov and on SEDAR at www.sedar.com.


    
                               Oncothyreon Inc.

     Consolidated Statements of Operations and Other Comprehensive Loss Data
                   (in thousands except per share amounts)
                                 (unaudited)

                                      Three Months Ended    Six Months Ended
                                             June 30             June 30
                                      ------------------  ------------------
                                          2009      2008      2009      2008
                                      --------  --------  --------  --------
    Revenue
      Contract manufacturing.........        -       802         -     2,520
      Licensing revenue from
       collaborative agreements......        4       350         8       652
      Licensing, royalties and
       other revenue.................       27         -        27         -
                                      --------  --------  --------  --------
                                            31     1,152        35     3,172
                                      --------  --------  --------  --------

    Expenses
      Research and development.......    1,995     2,726     2,675     5,034
      Manufacturing..................        -       646         -     2,726
      General and administrative.....    1,745     2,661     3,496     5,364
      Amortization...................       67       103       132       206
      Investment and other income....       54       (68)       34      (128)
      Change in fair value of
       warrant liability.............    2,502         -     2,502         -
                                      --------  --------  --------  --------
                                         6,363     6,068     8,839    13,202
                                      --------  --------  --------  --------
    Net loss.........................   (6,332)   (4,916)   (8,804)  (10,030)
    Other comprehensive income
     (loss)..........................        -        72         -       (31)
                                      --------  --------  --------  --------
    Comprehensive net loss........... $ (6,332) $ (4,844) $ (8,804) $(10,061)
                                      --------  --------  --------  --------
                                      --------  --------  --------  --------
    Basic and diluted loss per
     share........................... $  (0.30) $  (0.25) $  (0.43) $  (0.51)
                                      --------  --------  --------  --------
    Weighted average number of
     common shares outstanding.......   20,984    19.492    20,243    19.489
                                      --------  --------  --------  --------
                                      --------  --------  --------  --------



                               Oncothyreon Inc.

                       Consolidated Balance Sheets Data
                               (in thousands)
                                 (unaudited)

                                            June 30, 2009  December 31, 2008

    Cash, cash equivalents and short term
     investments...............................  $ 22,706           $ 19,166
    Total assets...............................  $ 28,110           $ 24,971
    Total long-term liabilities................  $  7,105           $    393
    Stockholders' equity.......................  $ 18,549           $ 20,717
    Common shares outstanding..................    23,371             19,492
    





For further information:

For further information: Investor and Media Relations Contact: Julie
Rathbun, Rathbun Communications, (206) 769-9219, ir@oncothyreon.com

Organization Profile

ONCOTHYREON INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890